NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia and Bluebee Partner to Bring New NGS-Based MammaPrint BluePrint Breast Cancer Kit to Market
IRVINE, CA, AMSTERDAM, and RIJSWIJK, NETHERLANDS โ 19 December 2017 โ Agendia, Inc, a world leader in personalized medicine and molecular cancer diagnostics, and Bluebee, a company driving global genomic data-driven medicine, have partnered to Read More
Key Studies Presented at the San Antonio Breast Cancer Symposium Demonstrate the Important Role of MammaPrint for Patient Pre-Selection, Cost-Effectiveness and For Younger Patients
ย Data from the I-SPY 2 trial showed the first long-term survival results for patients pre-selected as MammaPrint high-risk, with 94% of the patients who achieved pathological complete response event-free at three years MammaPrint assessment Read More
Agendia and UZ Leuven Partner to Co-Validate MammaPrint BluePrint Breast Cancer Risk of Recurrence and Molecular Subtyping Kit Ahead of European Launch
IRVINE, CA, AMSTERDAM, NETHERLANDS โ 7 December 2017 โ Agendia, a world leader in personalized medicine and molecular cancer diagnostics, and University Hospitals Leuven (UZ Leuven) in Belgium have partnered to co-validate Agendiaโs new in Read More